Aldeyra Sells Subsidiary for $10M
Ticker: ALDX · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1341235
| Field | Detail |
|---|---|
| Company | Aldeyra Therapeutics, INC. (ALDX) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, subsidiary-sale, financing
TL;DR
Aldeyra selling Adverum for $10M, closing Q3.
AI Summary
Aldeyra Therapeutics, Inc. announced on June 20, 2024, that it has entered into a definitive agreement to sell its subsidiary, Adverum Therapeutics, Inc., to a third party. The transaction is expected to close in the third quarter of 2024 and will result in Aldeyra Therapeutics receiving an upfront payment of $10 million.
Why It Matters
This divestiture allows Aldeyra Therapeutics to focus on its core pipeline and potentially improve its financial position through the cash infusion.
Risk Assessment
Risk Level: medium — The sale of a subsidiary can indicate strategic shifts or financial pressures, and the success of the remaining business is crucial.
Key Numbers
- $10.0M — Upfront Payment (Cash received from the sale of Adverum Therapeutics, Inc.)
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Registrant
- Adverum Therapeutics, Inc. (company) — Subsidiary being sold
- $10 million (dollar_amount) — Upfront payment for subsidiary sale
- June 20, 2024 (date) — Date of the report and announcement
- third quarter of 2024 (date) — Expected closing period for the transaction
FAQ
What is the exact nature of the definitive agreement for the sale of Adverum Therapeutics, Inc.?
The filing states Aldeyra Therapeutics, Inc. entered into a definitive agreement to sell its subsidiary, Adverum Therapeutics, Inc., to a third party.
When is the sale of Adverum Therapeutics, Inc. expected to be completed?
The transaction is expected to close in the third quarter of 2024.
What is the upfront payment Aldeyra Therapeutics will receive for the sale?
Aldeyra Therapeutics will receive an upfront payment of $10 million.
What is the primary business of Adverum Therapeutics, Inc.?
The filing does not explicitly detail the primary business of Adverum Therapeutics, Inc., only that it is a subsidiary of Aldeyra Therapeutics, Inc.
What is the filing date of this 8-K report?
This 8-K report was filed on June 20, 2024.
Filing Stats: 460 words · 2 min read · ~2 pages · Grade level 9.6 · Accepted 2024-06-20 07:01:40
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq
Filing Documents
- ea0208142-8k_aldeyra.htm (8-K) — 23KB
- ea020814201ex99-1_aldeyra.htm (EX-99.1) — 27KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- ex99-1_002.jpg (GRAPHIC) — 468KB
- ex99-1_003.jpg (GRAPHIC) — 506KB
- ex99-1_004.jpg (GRAPHIC) — 522KB
- ex99-1_005.jpg (GRAPHIC) — 606KB
- ex99-1_006.jpg (GRAPHIC) — 617KB
- ex99-1_007.jpg (GRAPHIC) — 518KB
- 0001213900-24-054003.txt ( ) — 4687KB
- aldx-20240620.xsd (EX-101.SCH) — 3KB
- aldx-20240620_lab.xml (EX-101.LAB) — 33KB
- aldx-20240620_pre.xml (EX-101.PRE) — 22KB
- ea0208142-8k_aldeyra_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On June 20, 2024, Aldeyra Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") to announce the advancement of new RASP modulators and recent preclinical data in obesity. As part of a virtual Investor Roundtable on June 20, 2024, the Company will discuss the announcement, among other topics. The Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Aldeyra Therapeutics, Inc. Press Release dated June 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALDEYRA THERAPEUTICS, INC. By: /s/ Todd C. Brady Name: Todd C. Brady, M.D., Ph.D. Title: Chief Executive Officer Dated June 20, 2024 2